VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT

Leukemia

Volumn 28, Issue 4, 2014, Pages 928-934

  Terpos, E ^a   Christoulas, D ^a   Kastritis, E ^a   Roussou, M ^a   Migkou, M ^a   Eleutherakis Papaiakovou, E ^a   Gavriatopoulou, M ^a   Gkotzamanidou, M ^a   Kanellias, N ^a   Manios, E ^a   Papadimitriou, C ^a   Dimopoulos, M A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

bone markers; consolidation; multiple myeloma; skeletal related events; VTD

Indexed keywords

ACETYLSALICYLIC ACID; ALKALINE PHOSPHATASE BONE ISOENZYME; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CARBOXY TERMINAL TELOPEPTIDE; COTRIMOXAZOLE; DEXAMETHASONE; LOW MOLECULAR WEIGHT HEPARIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; THALIDOMIDE; VALACICLOVIR; WARFARIN;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE DISEASE; BONE METABOLISM; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED ANEMIA; CLINICAL ARTICLE; CLINICAL EVALUATION; CONSTIPATION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; FATIGUE; FEMALE; HEART ARRHYTHMIA; HUMAN; INSOMNIA; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUTROPENIA; OSTEOLYSIS; PERIPHERAL NEUROPATHY; PNEUMONIA; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN STABILITY; REMISSION; SKELETAL RELATED EVENT; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE REMODELING; BONE RESORPTION; BORONIC ACIDS; DEXAMETHASONE; DIPHOSPHONATES; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PROSPECTIVE STUDIES; PYRAZINES; SERUM RESPONSE ELEMENT; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84898439909     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.267     Document Type: Article

References (22)

1. van Rhee F, Szymonifka J, Anaissie E, Nair B, Waheed S, Alsayed Y et al. Total therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide and dexamethasone, relevant to all phases of therapy. Blood 2010; 116: 1220-1227.
2. Leleu X, Fouquet G, Hebraud B, Roussel M, Caillot D, Chré tien ML et al. Consolidation with VTd significantly improves the complete remission rate and time to progression following VTdinduction and single autologous stem cell transplantation in multiple myeloma. Leukemia 2013; 27: 2242-2244.
3. Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL et al. Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. Ann Hematol 2012; 91: 249-256.
4. Cavo M, Pantani L, Petrucci MT, Patriarca F, Zamagni E, Donnarumma D et al. Bortezomib-thalidomide-dexamethasone is superior to thalidomide- dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. Blood 2012; 120: 1597-1600.
5. Ladetto M, Pagliano G, Ferrero S, Cavallo F, Drandi D, Santo L et al. Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. J Clin Oncol 2010; 28: 2077-2084.
6. Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factorkappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006; 135: 688-692. (Pubitemid 44674080)
7. Terpos E, Christoulas D, Kokkoris P, Anargyrou K, Gavriatopoulou M, Migkou M et al. Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid. Ann Oncol 2010; 21: 1561-1562.
8. Zangari M, Yaccoby S, Pappas L, Cavallo F, Kumar NS, Ranganathan S et al. A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated withbortezomib response in multiple myeloma patients. Haematologica 2011; 96: 333-336.
9. Terpos E, Morgan G, Dimopoulos M, Drake M, Lentzsch S, Raje N et al. International Myeloma Working Group recommendations for the treatment of multiple myeloma related bone disease. J Clin Oncol 2013; 31: 2347-2357.
10. Terpos E, Kastritis E, Roussou M, Heath D, Christoulas D, Anagnostopoulos N et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia 2008; 22: 2247-2256.
11. Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A et al. Bisphosphonates in multiple myeloma: a network meta-analysis. Cochrane Database Syst Rev 2012; 5: CD003188.
12. Clark RE, Flory AJ, Ion EM, Woodcock BE, Durham BH, Fraser WD. Biochemical markers of bone turnover following high-dose chemotherapy and autografting in multiple myeloma. Blood 2000; 96: 2697-2702.
13. Terpos E, Politou M, Szydlo R, Nadal E, Avery S, Olavarria E et al. Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. Leukemia 2004; 18: 1420-1426. (Pubitemid 39136753)
14. Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA et al. Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation. Int J Cancer 2006; 119: 1728-1731. (Pubitemid 44258784)
15. Terpos E, Mihou D, Szydlo R, Tsimirika K, Karkantaris C, Politou M et al. The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio. Leukemia 2005; 19: 1969-1976. (Pubitemid 41554006)
16. Tosi P, Zamagni E, Cellini C, Parente R, Cangini D, Tacchetti P et al. First-line therapy with thalidomide, dexamethasone and zoledronic acid decreases bone resorption markers in patients with multiple myeloma. Eur J Haematol 2006; 76: 399-404.
17. Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M et al. Dickkopf-1: a suitable target for the management of myeloma bone disease. Expert Opin Ther Targets 2009; 13: 839-848.
18. Delforge M, Terpos E, Richardson PG, Shpilberg O, Khuageva NK, Schlag R et al. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. melphalanprednisone in the phase III VISTA trial in multiple myeloma. Eur J Haematol 2011; 86: 372-384.
19. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 2010; 28: 2612-2624.
20. Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009; 114: 3139-3146.
21. McCarthy PL, Owzar K, Hofmeister CC, Hurd DD, Hassoun H, Richardson PG et al. Lenalidomide after stem cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1770-1781.
22. Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T et al. Lenalidomide maintenance after stem cell transplantation for multiple myeloma. N Engl J Med 2012; 366: 1782-1791.